COFEPRIS Just Made Clinical Research Approval Simpler in Mexico. Here’s What Changed.
Published: May 18, 2026 | bioaccess® Research and Regulatory Team
The Acuerdo and Its Limits
On May 4, 2026, Mexico’s Comisión Federal para la Protección contra Riesgos Sanitarios published a Diario Oficial de la Federación Acuerdo that took effect two days later, on May 6. The Acuerdo formalized mandatory digital submission of all clinical research protocols through DIGIPRiS — COFEPRIS’s electronic platform — and introduced an exemption category that removes the authorization requirement entirely for a defined class of low-risk studies. The headline reads as regulatory modernization. For a first-in-human founder evaluating Mexico as a clinical site, the reality is more textured than the headline suggests.
Mexico has long held structural advantages for clinical research that its regulatory timeline has historically undercut. It is the second-largest pharmaceutical market in Latin America. Its urban research sites in Mexico City and Monterrey are well-staffed and experienced. The patient population for therapeutic categories ranging from urology to metabolic disease is large. What founders and regulatory directors have historically encountered is a submission process that, by COFEPRIS’s own published data, averaged up to 400 days for clinical trial approval before the current modernization wave began.
The May 4 Acuerdo does not eliminate that history overnight. It signals a directional change — one that is already showing measurable effects in the data — and it introduces two specific operational shifts that matter more than the general narrative of “faster approvals”: a mandatory digital platform with concrete submission requirements, and an exemption classification that most non-Mexico-specialist CROs do not surface for their clients. Understanding both is how founders use this moment rather than simply noting it.
bioaccess® has operated across 10 Latin American countries since 2010, supporting 58 client companies through first-in-human programs. This post draws on that operational context to translate the Acuerdo from regulatory text into a practical framework for founders and regulatory affairs directors building or revising their LATAM clinical strategy.
What the Acuerdo Actually Changed
The May 4 DOF Acuerdo, published at sidof.segob.gob.mx/notas/5786604, mandates three operational shifts:
- DIGIPRiS is now the mandatory submission channel for all new clinical research protocols. Sponsors and CROs must submit new protocols, amendments, and technical reports exclusively through the DIGIPRiS portal. Legacy paper-based filing pathways are no longer accepted for new submissions. This applies regardless of study phase, therapeutic category, or sponsor geography. An active institutional account with delegated user roles — authorizer, editor, viewer — must be established before any submission clock starts. First-time submitters without existing platform credentials should allow 2–4 weeks for account setup and role delegation before protocol review begins.
- “Investigación sin riesgo” studies are fully exempt from COFEPRIS authorization. Mexico’s health research regulatory framework (Reglamento de la Ley General de Salud en Materia de Investigación para la Salud) classifies research into risk tiers. “Investigación sin riesgo” — no-risk research — covers studies that use documentary techniques, structured interviews, observation, and non-invasive physiological measurement without procedures that exceed standard clinical contact. Studies in this category do not require COFEPRIS authorization under the Acuerdo and do not submit through DIGIPRiS for authorization purposes. Device sponsors developing companion diagnostics, observational registries, or instrument-only studies should determine whether their study qualifies before assuming full COFEPRIS submission overhead. Misclassification in either direction costs time.
- Single-opportunity prevention and immediate resolution schemes. The Acuerdo introduces a single-opportunity rule for submission completeness — incomplete dossiers are flagged at intake rather than returned weeks into the review cycle. For defined categories, immediate resolution pathways are introduced. Both changes are designed to reduce the back-and-forth that historically inflated review timelines well beyond regulatory normatives.
Prior to the Acuerdo, DIGIPRiS had been in partial rollout since 2025. As of May 2026, the platform manages 90% of protocol amendment workflows. The transition to mandatory full-protocol submission through the same channel completes that digital migration. For CROs and sponsors with established accounts, this is an efficiency gain. For those entering Mexico for the first time, platform credentialing is now a prerequisite step, not a parallel task.
The 400-Day Baseline: What the Data Actually Says
Any accurate assessment of the Acuerdo’s significance requires anchoring in the numbers COFEPRIS itself has published. The agency’s Digitalización 2026 Plan — a 60-million-peso initiative with a December 2026 completion target, surfaced in mid-May 2026 — explicitly acknowledges that historical clinical trial approval times averaged up to 400 days prior to the current modernization wave. That number is not an advocacy figure. It is the baseline COFEPRIS used to set its own performance improvement targets.
Against that baseline, the 2025 DIGIPRiS implementation data is meaningful: average protocol approval times dropped from 90 to 45 calendar days between January and April 2025 as the platform was progressively deployed. Amendment reviews averaged 57 days — a 37% improvement over prior normatives. By May 2026, the platform manages 90% of amendment workflows. These numbers reflect a partial rollout; the full mandatory deployment that began May 6 will produce new performance data over the coming quarters.
The honest framing for a founder: the Acuerdo signals structural intent backed by published data. It does not transform Mexico’s regulatory environment overnight. Budget conservatively on timeline while treating the directional improvement as real. For programs that can align protocol submission with a Mexico study start, the compression from 90 to 45 days — let alone from 400 — is structurally significant.
The Fastest Route: COFEPRIS Reliance for Reference-Authority Protocols
For sponsors whose protocols have already received authorization from a WHO-recognized high-level regulatory authority — including the FDA, EMA, or MHRA — the fastest Mexico submission route is not the standard DIGIPRiS pathway. It is the COFEPRIS reliance mechanism published in the Diario Oficial de la Federación on March 24, 2025, as analyzed by Global Regulatory Partners.
Under the reliance framework, protocols already authorized by reference regulators receive an abbreviated COFEPRIS review with target timelines of:
- 30 business days for medical devices
- 45 business days for drugs and biologics
These timelines are not guarantees — they are regulatory normatives. But for a device sponsor who has already completed an FDA Early Feasibility Study, or whose protocol carries CE mark approval, the reliance pathway represents a materially faster entry than standard review. DIGIPRiS makes the submission process for reliance applications cleaner and more trackable than the legacy paper system.
The practical implication: device founders should confirm whether their existing FDA or EMA documentation qualifies their Mexico protocol for the reliance pathway before defaulting to standard submission. The 30-business-day target for devices under reliance — approximately six calendar weeks — positions Mexico competitively with other LATAM FIH markets when this pathway applies.
For sponsors evaluating Mexico as part of a U.S.-plus-LATAM clinical strategy, the reliance pathway and the standard DIGIPRiS route serve different program types. Reliance is the right tool for sponsors with prior reference-authority approval. DIGIPRiS standard review is the route for novel protocols. Knowing which applies to your study at the outset determines whether Mexico belongs in your Year 1 clinical plan or your Year 2.
Where Mexico Fits in a LATAM Clinical Portfolio
Mexico’s regulatory position in the LATAM FIH landscape is distinct from its regional peers. A direct comparison helps founders understand where Mexico fits in a multi-country program design.
| Country | Regulatory Authority | Target Review Timeline | Fastest Ethics Timeline | Key Pathway Feature |
|---|---|---|---|---|
| Colombia | INVIMA | ~30 days (authority) | ~15–18 days (targeted, experience-based) | Fastest FIH ethics timeline in LATAM; strong site density |
| Mexico | COFEPRIS | 30 BD (devices, reliance) / 45 BD (drugs, reliance) / 45 CD (standard DIGIPRiS) | 4–8 weeks (typical) | Reliance pathway for FDA/EMA-approved protocols; second-largest LATAM pharma market |
| Brazil | ANVISA | 90 days (parallel review, RDC 945/2024) | Concurrent with ANVISA review | Parallel ethics and authority review; largest LATAM market by patient volume |
| Argentina | ANMAT | 62 days (Disposición 7516/2025) | Concurrent with ANMAT review | Streamlined 62-day normative; strong oncology and metabolic disease site base |
Colombia remains the fastest LATAM jurisdiction for first-in-human medical device studies on a combined authority-plus-ethics basis. For sponsors whose primary objective is speed to FIH data, Colombia typically anchors the program.
Mexico’s distinct value is patient population size, strong research sites in Mexico City and Monterrey, and — post-Acuerdo — a materially improved submission process for both standard and reliance pathways. It is not the fastest LATAM market, but it is increasingly competitive for sponsors requiring large patient pools, FDA/EMA-eligible reliance, or a Mexico regulatory track record for commercial purposes. For a multi-country program — Colombia for FIH speed, Mexico for expanded cohort enrollment — the post-Acuerdo improvement changes the sequencing calculus.
What Founders Should Do Now
If Mexico is in your clinical plan for 2026 or 2027, three actions should happen before your next protocol submission discussion:
- Establish DIGIPRiS credentialing immediately. The platform requires institutional account setup, user role delegation, and CRO authorization documentation. This is not a same-day process. For sponsors working with a CRO that already holds active DIGIPRiS credentials, this step is absorbed into existing infrastructure. For sponsors engaging a CRO for the first time, confirm credential status before the contract is signed. A CRO without an active account adds 2–4 weeks before your protocol review clock starts — time that has nothing to do with the regulatory review itself.
- Determine if your study qualifies as “investigación sin riesgo.” Sponsors developing observational registries, companion diagnostics, or non-invasive measurement instruments should review their study design against the risk classification framework before assuming full COFEPRIS submission overhead. A regulatory classification confirmation at protocol design stage is a 2–3 day exercise. Misclassification costs 4–8 weeks.
- Confirm your protocol’s reliance eligibility. If your study has received FDA or EMA authorization, the reliance pathway targets 30 business days for devices and 45 business days for drugs. This is the fastest available COFEPRIS review track and requires specific documentation at submission. DIGIPRiS submission under the reliance pathway follows the same platform process as standard review but with a different regulatory dossier structure. Confirm reliance eligibility and documentation requirements with your CRO before drafting the submission package.
Navigating DIGIPRiS requires an institutional account with established COFEPRIS relationships, documented sponsor delegation, and a track record of dossier completeness under the single-opportunity rule. A first-time submitter absorbs the platform learning curve on your protocol’s timeline. A CRO with active Mexico credentials absorbs it before your protocol arrives.
Three Questions to Determine Whether Mexico Belongs in Your 2026 Clinical Plan
The Acuerdo doesn’t change the fundamental logic of LATAM site selection for FIH programs. It changes one variable — submission timeline and process — in a direction that favors Mexico more than the previous two years did. The three questions that determine whether that change is material for your program:
- Does your protocol have FDA, EMA, or MHRA authorization? If yes, the COFEPRIS reliance pathway positions Mexico’s device review at 30 business days — competitive with Colombia on a combined basis for sponsors who don’t need ultra-fast ethics timelines. If no, standard DIGIPRiS review timelines apply and Colombia likely leads on speed.
- Does your primary endpoint require a large patient pool that a single Colombia site cannot support? Mexico’s site density in Mexico City and Monterrey, combined with the post-Acuerdo submission improvement, makes Mexico a natural partner for expanded cohort enrollment in programs that opened in Colombia. For sponsors needing 30–50+ patients in a single FIH program, a Colombia-plus-Mexico multi-site design may be the right structure.
- Is Mexico a target commercial market? If your device’s commercial path includes Mexico — a market of 130 million people with a growing private healthcare sector — building a Mexico regulatory track record at FIH stage is not just a trial design question. It is a commercial infrastructure question. The DIGIPRiS improvement makes it less costly to establish that track record early.
If you answer yes to any of these three questions, Mexico belongs in your 2026–2027 clinical planning discussion. The Acuerdo gave it a better position on the board than it held twelve months ago.
Next Steps
If you are evaluating Mexico as part of a LATAM FIH or multi-country clinical program, the time to establish DIGIPRiS infrastructure and confirm your study’s regulatory classification is before your protocol is finalized — not after. The window where Mexico’s post-Acuerdo momentum aligns with available site capacity and a CRO team already credentialed on the platform is now.
Book a meeting to discuss where Mexico fits in your clinical strategy, or use the clinical trial cost calculator to model per-patient and total program costs across LATAM jurisdictions.
Sources
- COFEPRIS DOF Acuerdo May 4, 2026 — Diario Oficial de la Federación
- COFEPRIS DIGIPRiS Portal — gob.mx/cofepris
- bioaccess® Mexico regulatory explainer — bioaccessla.com
- bioaccess® Argentina 62-day approval guide — bioaccessla.com
- bioaccess® Brazil ANVISA RDC 945/2024 guide — bioaccessla.com
- Global Regulatory Partners — COFEPRIS reliance pathway analysis
- FDA Early Feasibility Studies Program — fda.gov
- 21 CFR 312.120 — Foreign Clinical Studies Not Conducted Under an IND
